Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02799745 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance
A Phase 2 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
NCT02799745 is a Phase 2 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 227 participants.
The verdict
NCT02799745, a Phase 2 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
Study Summary
The primary purpose of this study was to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance.
Interventions
- OTHER Active Surveillance
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2016-06-09 |
| Est. Completion | 2020-08-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02799745
The ClinicalTrials.gov registry entry for NCT02799745 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Active Surveillance is the first listed.
NCT02799745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02799745 about?
NCT02799745 is a clinical study titled "A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance". The primary purpose of this study was to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance.
What is the current status of trial NCT02799745?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2016-06-09. Estimated completion is 2020-08-28.
What interventions are being tested in trial NCT02799745?
The interventions under investigation include: Active Surveillance (OTHER), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02799745?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.